H. T. Hoffman, L. H. Karnell, G. F. Funk, et al., “The National Cancer Data Base Report on Cancer of the Head and Neck,” Archives of Otolaryngology—Head and Neck Surgery, Vol. 124, No. 9, 1998, pp. 951-962.
 S. Silverman, “Demographics and Occurrences of Oral and Pharyngeal Cancers. The Outcomes, the Trends, the Challenge,” The Journal of the American Dental Association, Vol. 132, Supplement 7S-11S, 2001, pp. 7s-11s.
 L. G. Morris, A. G. Sikora, R. B. Hayes, S. G. Patel and I. Ganly, “Anatomic Sites at Elevated Risk of Second Primary Cancer after an Index Head and Neck Cancer,” Cancer Causes & Control, Vol. 22, No. 5, 2011, pp. 671-679. doi:10.1007/s10552-011-9739-2
 R. Rattan, R. Ali Fehmi and A. Munkarah, “Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis,” Journal of Oncology, Vol. 2012, 2012, Article ID: 928127. doi:10.1155/2012/928127
 K. Hosono, H. Endo, M. Sugiyama, et al., “Metformin Suppresses Colorectal Aberrant Crypt Foci in a ShortTerm Clinical Trial,” Cancer Prevention Research (Philadelphia), Vol. 3, No. 9, 2010, pp. 1077-1083. doi:10.1158/1940-6207.CAPR-10-0186
 T. M. Chen, C. C. Lin, P. T. Huang and C. F. Wen, “Metformin Associated with Lower Mortality in Diabetic Patients with Early Stage Hepatocellular Carcinoma after Radiofrequency Ablation,” Journal of Gastroenterology and Hepatology, Vol. 26, No. 5, 2011, pp. 858-865. doi:10.1111/j.1440-1746.2011.06664.x
 N. Sadeghi, J. L. Abbruzzese, S. C. Yeung, M. Hassan and D. Li, “Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer,” Clinical Cancer Research, Vol. 18, No. 10, 2012, pp. 2905-2912. doi:10.1158/1078-0432.CCR-11-2994
 L. Vitale-Cross, A. A. Molinolo, D. Martin, et al., “Metformin Prevents the Development of Oral Squamous Cell Carcinomas from Carcinogen-Induced Premalignant Lesions,” Cancer Prevention Research (Philadelphia), Vol. 5, No. 4, 2012, pp. 562-573. doi:10.1158/1940-6207.CAPR-11-0502
 S. Jiralerspong, S. L. Palla, S. H. Giordano, et al., “Metformin and Pathologic Complete Response to Neoadjuvant Chemotherapy in Diabetic Patients with Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 20, 2009, pp. 3297-3302. doi:10.1200/JCO.2009.19.6410
 H. P. Chen, J. J. Shieh, C. C. Chang, et al., “Metformin Decreases Hepatocellular Carcinoma Risk in a DoseDependent Manner: Population-Based and in Vitro Studies,” Gut, Vol. 62, No. 4, 2013, pp. 606-615.
 C. H. Tseng, “Diabetes, Metformin Use, and Colon Cancer. A Population-Based Cohort Study in Taiwan,” European Journal of Endocrinology, Vol. 167, No. 3, 2012, pp. 409-416. doi:10.1530/EJE-12-0369
 M. F. McCarty, “MTORC1 Activity as a Determinant of Cancer Risk-Rationalizing the Cancer-Preventive Effects of Adiponectin, Metformin, Rapamycin, and Low-Protein Vegan Diets,” Medical Hypotheses, Vol. 77, No. 4, 2011, pp. 642-648. doi:10.1016/j.mehy.2011.07.004
 H. D. Skinner, V. C. Sandulache and T. J. Ow, et al., “TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence,” Clinical Cancer Research, Vol. 18, No. 1, 2012, pp. 290-300. doi:10.1158/1078-0432.CCR-11-2260
 S. Sklenicka, S. Gardiner, E. J. Dierks, B. E. Potter and R. B. Bell, “Survival Analysis and Risk Factors for Recurrence in Oral Squamous Cell Carcinoma: Does Surgical Salvage Affect Outcome?” Journal of Oral and Maxillofacial Surgery, Vol. 68, No. 6, 2010, pp. 1270-1275. doi:10.1016/j.joms.2009.11.016
 D. H. Lee, M. J. Kim, J. L. Roh, et al., “Distant Metastases and Survival Prediction in Head and Neck Squamous Cell Carcinoma,” Otolaryngology—Head and Neck Surgery, Vol. 147, No. 5, 2012, pp. 870-875. doi:10.1016/j.joms.2009.11.016